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Abstract
Background: Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic
arthritis (polyJIA) treated with adalimumab, etanercept, or tocilizumab were analyzed in clinical practice.
Methods: Data collected in the German BIKER registry were analyzed in patients with polyJIA who started
treatment with approved biologics, adalimumab, etanercept or tocilizumab, from 2011 to 2015. Baseline patient
characteristics, treatment response, safety and drug survival were compared.
Results: Two hundred thirty-six patient started adalimumab, 419 etanercept and 74 tocilizumab, with differences in
baseline patient characteristics. Baseline Juvenile Disease Activity Score (JADAS)10 (mean ± SD) in the adalimumab/
etanercept/tocilizumab cohorts was 12.1+/−7.6, 13.8 ± 7.1 and 15.1 ± 7.4, respectively (adalimumab vs etanercept,
p = 0.01), and Childhood Health Assessment Questionnaire (CHAQ)-disability index scores was 0.43 ± 0.58, 0.59 ± 0.6
and 0.63 ± 0.55, respectively (adalimumab vs etanercept, p < 0.001). Uveitis history was more frequent in the
adalimumab cohort (OR 5.73; p < 0.001). Balanced patients’ samples were obtained by a generalized propensity
score to adjust for baseline differences. Pediatric ACR30/50/70/90 criterion improvement after 3 months treatment
was achieved by 68%/60%/42%/24% in the etanercept cohort, 67%/59%/43%/27% in the adalimumab cohort and
61%/52%/35%/26% in the tocilizumab cohort. At 24 months, JADAS minimal disease activity was achieved in 52.
4%/61.3%/52.4% and JADAS remission in 27.9%/34.8%/27.9% patients in the adalimumab/etanercept/tocilizumab
cohorts, respectively. Etanercept was used in 95.5% of patients as a first biologic, adalimumab in 50.8% and
tocilizumab in 20.2%. There were no important differences in efficacy between first-line and second-line use of
biologics. In total 60.4%/49.4%/31.1% patients discontinued adalimumab/etanercept/tocilizumab, respectively (HR
for adalimumab 1.67; p < 0.001; HR for tocilizumab 0.35; p = 0.001). Drug survival rates did not differ significantly in
patients on biologic monotherapy compared with combination therapy with methotrexate. Over 4 years
observation under etanercept/adalimumab/tocilizumab, 996/386/103 adverse events, and 148/119/26 serious
adverse events, respectively, were reported.
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Conclusions: In clinical practice, etanercept is most frequently used as first-line biologic. Adalimumab/etanercept/
tocilizumab showed comparable efficacy toward polyJIA. Overall, tolerance was acceptable. Interestingly,
compliance was highest with tocilizumab and lowest with adalimumab. This study provides the first indication for
the comparison of different biologic agents in polyarticular JIA based on observational study data with all their
weaknesses and demonstrates the need for well-controlled head-to-head studies for confirmation.
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Background
Juvenile idiopathic arthritis (JIA) is a collective term for
arthritides that are diagnosed before the age of 16 years.
Diagnosis requires disease duration of at least 6 weeks
and the exclusion of other causes of arthritis [1]. JIA is
the most common chronic rheumatic inflammatory dis-
ease of childhood. If not successfully treated, it can lead
to severe disability [2].
Pharmacologic treatment consists of nonsteroidal anti-
rheumatic drugs, mainly for symptomatic relief, and
disease-modifying antirheumatic drugs (DMARDs). Of
the latter group, methotrexate (MTX) is the most com-
mon first-line DMARD and is a cornerstone drug in the
treatment of patients with JIA. Its efficacy was first dem-
onstrated two decades ago in a randomized controlled
trial [3]. According to national and international guide-
lines and recommendations, patients with JIA who are
refractory to MTX treatment are eligible for treatment
with biologic agents [4, 5].
Etanercept, an anti-TNF-α receptor immunoglobulin Fc
fragment fusion protein, was the first biologic agent
approved by the US Food and Drug Administration for the
treatment of polyarticular JIA (pJIA) in 1999 and by the
European Medicines Evaluating Agency in 2000. Its efficacy
and safety were demonstrated in a randomized controlled
withdrawal trial and several long-term observational studies
from national registries, including the German Biologics in
Pediatric Rheumatology (BIKER) Registry [6–9]. In 2008,
adalimumab, a monoclonal anti-TNF-α antibody, was
approved for the treatment of polyarticular JIA, as mono-
therapy or in combination with MTX, after its efficacy was
established in a placebo-controlled withdrawal trial [10].
Adalimumab was preferred over etanercept for the treat-
ment of uveitis for years until a recent randomized placebo
controlled trial demonstrated its efficacy for treatment of
uveitis [11]. Observational data on the use of adalimumab
for JIA are more limited than those on the use of etanercept
[12]. Tocilizumab, a monoclonal interleukin-6 receptor
antibody, was first approved for systemic onset JIA in 2011
and was found to be effective in a randomized controlled
withdrawal trial [13]. Since 2013, Tocilizumab has been the
third first-line biologic agent approved for treatment of
polyarticular JIA.
The efficacy of these three agents for the treatment of
JIA is considered to be equivalent [14]. However, no
head-to-head trials have been conducted to compare
etanercept, adalimumab or tocilizumab. All three bio-
logic agents are approved for treatment of polyarticular
JIA in children older than 2 years who do not respond
to MTX. Therefore, the initial decision of which biologic
agent to use must be determined based on limited evi-
dence. The aim of this analysis was to compare baseline
characteristics, efficacy, tolerability and drug survival in
patients with polyarticular JIA initiating adalimumab,
etanercept or tocilizumab.
Methods
The German BIKER Registry was approved by the local
ethics committee. Written consent was obtained and
pseudonymized data were collected. This registry has been
extensively described in previous reports [9, 15]. Patients
in the German BIKER registry initiating treatment with
adalimumab, etanercept or tocilizumab between 1 January
2011 and 31 December 2015 were included in the study.
The study population was restricted to patients who were
classified in the following JIA categories: rheumatoid
factor-positive polyarthritis, rheumatoid factor-negative
polyarthritis and extended oligoarthritis. Patients with
other JIA categories (systemic onset JIA, persistent
oligoarthritis, psoriatic arthritis (PsA), enthesitis-related
arthritis (ERA) and unclassified JIA) were excluded be-
cause of differences in the approval of the three biologics
studied and to homogenize the study population.
For the efficacy analyses, assessments were performed at
baseline and at follow up after 3 and 6 months and every
6 months thereafter. Due to the character of the registry
study, the number of patients observed decreased with
treatment duration. For this reason, efficacy was analyzed
until month 24. Juvenile Disease Activity Score (JADAS)
scores and improvement in the Pediatric American College
of Rheumatology Criteria (PedACR) were calculated as
previously described in detail [16, 17]. The JADAS minimal
disease activity (MDA) (defined as JADAS10 ≤ 3.8) and
JADAS remission rates (defined as JADAS10 ≤ 1) accord-
ing to the definition of Consolaro et al. [18] were calcu-
lated. The JADAS10 was chosen because all four domains,
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number of active joints (truncated at 10), patient’s/parent’s
global assessment of disease activity, physician’s global
assessment of disease activity, and erythrocyte sedimenta-
tion rate, ranged from 0 to 10 points. Functional status was
determined using the Childhood Health Assessment Ques-
tionnaire (CHAQ) disability index [19].
Safety was analyzed based on adverse event reporting.
An adverse event was defined as any untoward medical
occurrence in a subject administered a pharmaceutical
product, even without a causal relationship with the
treatment. Serious adverse events included death, a life-
threatening event or an event leading to or prolonging
hospitalization, persistent or significant disability/incap-
acity or an important medical event requiring medical or
surgical intervention to prevent a serious outcome or
congenital anomaly or birth defect. For this analysis,
reasons for discontinuation were classified as inefficacy,
intolerance, remission or other reasons.
Statistical analysis
The adalimumab, etanercept and tocilizumab cohorts dif-
fered in their clinical characteristics and treatment history
at baseline. A generalized propensity score was estimated
to obtain balanced samples of patients in respect to base-
line characteristics. The likelihood of being allocated to a
cohort was estimated by a multinomial logistic regression
model, including the predictors, sex, age at JIA onset, JIA
category, disease duration, JADAS10, concomitant MTX
use and the number of previously used biologic agents.
Balanced samples of patients were obtained using an in-
verse probability of treatment weight. Generalised estima-
tion equations (GEE) were applied to the weighted sample
of patients to analyze the drug adherence and treatment
response. Drug survival was analyzed by Kaplan-Meier
plots and Cox proportional hazard model.
Results
Study population
The German BIKER registry database of 3547 patients
with JIA was used to identify eligible patients. Patients
diagnosed with rheumatoid factor-positive polyarthritis,
rheumatoid factor-negative polyarthritis or extended oli-
goarthritis, who had initiated treatment with a biologic
agent from 1 January 2011 to 31 December 2015, were
considered. Up to December 2015, 236 patients started on
adalimumab, 419 started on etanercept and 74 started on
tocilizumab.
Clinical characteristics at treatment initiation signifi-
cantly differed between the three groups (Additional file 1:
Table S1). The propensity-score-weighted analyses of
baseline characteristics resulted in balanced samples as re-
ported in Table 1 except for sex and uveitis. Female pre-
dominance was more pronounced in the etanercept and
adalimumab cohorts than in the tocilizumab cohort
(Table 1). Compared with the etanercept cohort, patients
in the adalimumab or tocilizumab cohort were slightly
older. The distribution of the three analyzed JIA categories
was comparable among medications despite a lower rate
of patients diagnosed with extended oligoarthritis in the
tocilizumab cohort compared with the other two cohorts
combined.
Etanercept was used as a first biologic agent in 583 pa-
tients (79.9%), adalimumab in 174 patients (23.9%) and
tocilizumab in 17 patients (2.3%). Thus, etanercept was
preferred as a first-line biologic agent. Only 17 patients
(4.1%) received etanercept as a second-line biologic
agent. In the adalimumab cohort, approximately half
(46.6%) of the patients received adalimumab as the first
biologic agent, while only 18.9% in the tocilizumab
cohort received tocilizumab as the first biologic agent.
Compared with the etanercept cohort, the baseline
JADAS10 and CHAQ-disability index were lower in the
adalimumab cohort. Concomitant uveitis was present in
23 (5.5%) of the etanercept cohort, in 58 (25%) of the
adalimumab cohort and in no patients in the toci-
lizumab cohort. Thus, uveitis demonstrated the highest
frequency in patients treated with adalimumab (odds ra-
tio 3.41 (95% CI 3.21; 4.45); p = 0.03).
At baseline, 302 patients (72%) in the etanercept
cohort but only 127 (54%) in the adalimumab and 34
(46%) in the tocilizumab cohort received concomitant
therapy with MTX. The differences described were not
statistically significant after weighting the analyses with
the propensity score weight (Table 1).
Treatment response
The mean treatment duration was comparable among
all cohorts (1.25 ± 1.05 years in the etanercept cohort,
1.0 ± 0.86 in the adalimumab cohort and 0.98 ± 0.59 in
the tocilizumab cohort). Improvement according to Ped-
ACR30/50/70/90 criteria was reached after 3 months by
68%/60%/42 %/24 % in the etanercept cohort, 67%/59%/
43%/27% in the adalimumab cohort and 61%/52%/35%/
26% in the tocilizumab cohort, respectively. The re-
sponse rates further increased or were stable with con-
tinuing treatment (Fig. 1). There were no statistically
significant differences between the three groups in the
PedACR response rates. PedACR response rates to
etanercept/adalimumab/tocilizumab, either as first-line or
second-line biologic agents, were comparable (Additional
file 2: Figure S1).
At baseline, the mean observed JADAS10 was highest
in the tocilizumab (15.1 ± 7.4) and etanercept (13.8 ± 7.1)
cohorts (p > 0.05) and significantly lower in the adalimu-
mab cohort (12.1 ± 7.6; p = 0.003 compared to etaner-
cept; p = 0.011 compared to tocilizumab). The significant
differences in baseline JADAS10 disappeared after
weighting the analyses (Table 1, Fig. 2).
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A significant decrease in the adjusted JADAS10 was
observed in all three cohorts (Fig. 2). From baseline to
the last observation on treatment, the JADAS10 de-
creased by 8.6 (95% CI 7.6; 9.5) points in the etanercept
cohort, by 7.3 (95% CI 5.8; 8.6) in the adalimumab
cohort and by 5.1 (95% CI 1.5; 8.4) in the tocilizumab
cohort. The decrease in JADAS10 did not significantly
differ among the three cohorts. The mean decrease in
JADAS10 was −7.7 (95% CI −8.47; −6.99) in patients
with rheumatoid factor-negative polyarthritis or extended
Fig. 1 Improvement in patients using etanercept, adalimumab or tocilizumab according to the Pediatric American College of Rheumatology
(PedACR)30/50/70 and 90 criteria
Table 1 Patients’ characteristics (absolute number of patients, percentages, descriptive statistics as reported in BIKER; comparison













n = 419 n = 236 n = 74 OR (95% CI); p value OR (95% CI); p value OR (95% CI); p value
Female, n (%) 332 (79.2%) 192 (81.4%) 51 (68.8%) 0.96 (0.57; 1.62); 0.88 0.63 (0.45; 0.89); 0.03 0.58 (0.48; 0.98); 0.04
Age at baseline, years,
mean ± SD
10.5 ± 4.4 11.8 ± 4.0 12.9 ± 3.6 0.63 (−0.31; 1.57); 0.19 1.65 (−0.67; 3.96); 0.16 1.02 (−1.31; 3.34); 0.39




3.6 ± 3.3 5.8 ± 4.0 6.1 ± 3.5 0.40 (−0.17; 0.98); 0.17 1.13 (−0.05; 2.02); 0.07 0.73 (−0.21; 1.66); 0.13
Median (IQR) 2.6 (1.1–5.1) 4.9 (2.4–8.4) 5.8 (2.9–8.8)
JIA category n (%)
RF+ PA 37 (8.8%) 23 (9.7%) 9 (12.2%) 1.45 (0.74; 2.83); 0.28 0.95 (0.60; 1.49); 0.81 2.18 (0.48; 9.85); 0.31
RF- PA 224 (53.5%) 128 (54.2%) 47 (63.5%) (ref) (ref) (ref)
ExOA 158 (37.7%) 85 (36.0%) 18 (24.3%) 3.17 (0.74; 13.60); 0.12 0.71 (0.22; 2.27); 0.57 0.75 (0.24; 2.41); 0.63
First biologic used 400 (95.5%) 110 (46.6%) 14 (18.9%) 0.54 (0.28; 1.03); 0.06 0.44 (0.16; 1.18); 0.10 0.81 (0.34; 1.96); 0.65
Co-med corticosteroids,
n (%)
134 (32.0) 60 (25.4) 26 (35.1) 1.38 (0.96; 1.97) 1.15 (0.69; 1.94) 1.59 (091; 2.78)
Co-med MTX, n (%) 302 (72.1) 127 (53.8) 34 (45.9) 1.20 (0.76; 1.88); 0.44 0.76 (0.28; 2.06); 0.59 0.64 (0.24; 1.70); 0.37
JADAS10 (0–40),
mean ± SD
13.8 ± 7.1 12.1 ± 7.6 15.1 ± 7.4 −0.41 (−2.30; 1.48); 0.67 −0.53 (−4.22; 3.17); 0.78 −0.12 (−3.84; 3.60); 0.95
Median (IQR) 13.6 (8.8–19.0) 11.7 (6.1–17.5) 14.8 (9.2–20.1)
CHAQ-DI (0–3),
mean ± SD
0.59 ± 0.60 0.43 ± 0.58 0.63 ± 0.55 −0.04 (−0.19; 0.12); 0.64 −0.10 (−0.30; 0.11); 0.35 −0.06 (−0.29; 0.17); 0.60
Median (IQR) 0.38 (0.13–0.88) 0.13 (0–0.623) 0.63 (0.19-1.0)
Uveitis before
start of biologic
23 (5.5%) 59 (25%) 0 3.41 (3.21; 4.45); 0.03 - -
aAnalyses weighted by an inverse probability of treatment estimated by a generalized propensity score. beta regression coefficient for continuous variables, CI
confidence interval, OR odds ratio for categorical variable, (ref) reference group, JIA juvenile idiopathic arthritis, RF rheumatoid factor, PA, polyarthritis, ExOA
extended oligoarthritis, JADAS Juvenile Disease Activity Score, CHAQ-DI Childhood Health Assessment Questionnaire disability index
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oligoarthritis, and −9.4 (95% CI −12.13; −6.63) for
rheumatoid factor-positive polyarthritis. The difference
between the JIA categories in the JADAS10 response was
not statistically significant (delta = 1.51; 95% CI −0.54;
3.56; p = 0.149).
JADAS remission and JADAS-MDA were used as fur-
ther treatment response indicators. In the etanercept,
adalimumab and tocilizumab cohorts, 131 patients
(34.8%), 71 patients (27.9%) and 16 patients (23.5%),
respectively, achieved JADAS remission (defined as
JADAS10 ≤ 1.0) at the last observation. The three co-
horts did not significantly differ in JADAS remission at
the last observation adjusting for baseline differences be-
tween the three cohorts. The rates of achieving JADAS-
MDA were comparable among all three cohorts (Fig. 3):
231 patients (61.3%), 133 patients (52.4%) and 32
patients (47.1%) in the etanercept, adalimumab and
tocilizumab cohorts, respectively, achieved JADAS-MDA
(defined as JADAS10 ≤ 3.8) at the last observation.
Patients who were first exposed to biologic agents
were compared to those who switched from a first to a
second biologic agent. The mean (± SD) JADAS10 in the
cohort previously exposed to a biologic agent (14.8 ± 7.3)
was not significantly lower than that in the biologic-
agent-naïve cohort (16.5 ± 7.2). The decline in JADAS10
at 3, 6, 12, 18 and 24 months, respectively, was 3.9 ± 3.3,
6.2 ± 7.4, 9.6 ± 7.7, 6.6 ± 5.9 and 2.9 ± 2.4 in the biologic-
naïve group, and 8.9 ± 6.5, 7.6 ± 8.2, 4.6 ± 5.6, 3.2 ± 4.5
and 7.7 ± 8.8 in the cohort switching from a first to a
second biologic. The decline in JADAS and the rates of
achieving JADAS remission and JADAS- MDA were
again comparable among the cohorts.
Functional disability was analyzed using the CHAQ-DI.
The observed baseline CHAQ-DI was highest in the
Fig. 2 Improvement in patients following etanercept, adalimumab or tocilizumab treatment according to Juvenile Disease Activity Score (JADAS)10 at
baseline compared with the last observation on a study drug
Fig. 3 Rates of Juvenile Disease Activity Score (JADAS)10 remission and minimal disease activity in patients taking etanercept, adalimumab
or tocilizumab
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tocilizumab cohort (0.63 ± 0.55), followed by the etanercept
cohort (0.59 ± 0.60) and the adalimumab cohort (0.43 ±
0.58). However, the baseline CHAQ-DI did not differ
among the three cohorts in the propensity-score-weighted
analyses. Reductions in CHAQ-DI from baseline to the last
observation in the tocilizumab, etanercept and adalimumab
cohorts were (−0.31 ± 0.46), (−0.22 ± 0.54) and (−0.12 ±
0.47), respectively. Reduction in the CHAQ-DI was signifi-
cantly greater in the etanercept cohort than in the adalimu-
mab cohort (p = 0.032). There was no significant difference
in the reduction in the CHAQ-DI between the tocilizumab
and the etanercept cohort (p = 0.261). However, the residual
CHAQ-DI at the last observation was comparable among
all three cohorts (etanercept 0.31 ± 0.44, adalimumab 0.29
± 0.48 and tocilizumab 0.36 ± 0.46).
Drug adherence and discontinuations
Drugs were discontinued by 142 patients (60.2%) in the
adalimumab cohort versus 207 patients (49.4%) in the
etanercept cohort and 23 patients (31.1%) in the toci-
lizumab cohort. The median drug survival before discon-
tinuation due to inefficacy or intolerance was 2.85 years
for adalimumab and 4.29 years for etanercept; this was
not calculated for tocilizumab because more than 50% of
the patients were still receiving treatment (Fig. 4). Sur-
vival analyses using Cox proportional hazard regression
revealed significant differences between adalimumab and
etanercept survival (hazard ratio 2.82, 95% CI 1.55; 5.14;
p < 0.001), between adalimumab and tocilizumab survival
(hazard ratio 4.71, 95% CI 2.58; 8.61; p < 0.001), and be-
tween etanercept and tocilizumab survival (hazard ratio
2.82, 95% CI 1.55; 5.14; p = 0.001).
Drug survival with adalimumab (hazard ratio 1.36,
95% CI 1.03; 1.78; p = 0.029) was improved but was sig-
nificant lower compared to etanercept when restricting
the analyses to patients who took etanercept and adali-
mumab as their first biologic agents. Interestingly, the
survival rates of patients on monotherapy with a biologic
agent compared with combination therapy with MTX
were not significantly different (p = 0.836) regardless of
whether they were calculated separately in the etanercept,
adalimumab or tocilizumab cohort (data not shown) or for
the combined analysis (Additional file 3: Figure S2).
Patients with rheumatoid factor-negative polyarthritis or
extended oligoarthritis had a comparable drug survival to
patients with rheumatoid factor-positive polyarthritis (haz-
ard ratio = 0.995, 95% CI 0.67; 1.47; p = 0.98). Drug survival
also did not statistically significantly differ between the JIA
categories in the adalimumab (hazard ratio = 1.15, 95% CI
0.62; 2.12; p = 0.653) and etanercept (hazard ratio = 0.83,
95% CI 0.48; 1.43; p = 0.502) cohorts.
The reasons for discontinuation are provided in Table 2.
The most common reason for discontinuation was poor ef-
ficacy or unsatisfactory response. Significantly more pa-
tients discontinued adalimumab (odds ratio 4.89, 95% CI
1.65; 14.48; p = 0.004) for reasons of inefficacy (n = 52
(22%)) than tocilizumab (n = 9 (12.2%)). Remission was the
second leading reason for discontinuation of a biologic
Fig. 4 Drug survival during treatment with etanercept (ETA), adalimumab (ADA) or tocilizumab (TOC); weighted Kaplan-Meier analyses weighted
by an inverse probability of treatment estimated by a generalized propensity score. Significant differences were noted, using the Cox proportional
hazard model, between the cohorts treated with adalimumab versus etanercept (p < 0.001, hazard ratio 0.60 (0.48–0.75)), adalimumab versus
tocilizumab (p = 0.001, hazard ratio 0.21 (0.12 − 0.39)) and tocilizumab versus etanercept (p < 0.001, hazard ratio 2.82 (1.55 − 5.14))
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n = 419 n = 236 n = 74 OR (95% CI); p value OR (95% CI); p value OR (95% CI); p value
Discontinuations, n (%) 207 (49.4) 142 (60.4) 23 (31.1) 1.57 (1.03; 2.41); 0.037 0.20 (0.09; 0.45); <0.001 0.13 (0.06; 0.29); <0.001
Inefficacy, n (%) 50 (11.9) 52 (22.0) 9 (12.2) 1.65 (0.88; 3.08); 0.118 0.34 (0.11; 1.00); 0.050 0.20 (0.07; 0.60); 0.004
Remission, n (%) 54 (12.9) 22 (9.3) 2 (2.7) 0.78 (0.43; 1.40); 0.404 0.12 (0.02; 0.79); 0.027 0.16 (0.02; 1.05); 0.056




Infections (4)b Impetigo (1)




Pustulosis (1), neuro-psychiatric (5)b 0.2 5
Others*, n (%) 88 (16.0) 53 (22.4) 10 (13.4) 1.21 (0.74; 1.96); 0.443 0.27 (0.10; 0.72); 0.009 0.22 (0.08; 0.60); 0.003
aAnalyses weighted by an inverse probability of treatment estimated by a generalized propensity score. bInfections included pneumonia and soft tissue infections; Neuropsychiatric included headache, nausea,














agent. Significantly more patients discontinued etanercept
due to remission (n = 54 (12.9%; odds ratio 8.24 (95% CI
1.27; 53.53); p = 0.027) than tocilizumab (n = 2 (2.7%)). In
general, few patients discontinued due to intolerance
(etanercept, n = 15 (3.6%); adalimumab, n = 15 (6.4%); toci-
lizumab, n = 2 (2.7%)). Patients treated with adalimumab
had a higher odds for discontinuation due to intolerance
(odds ratio 2.28, 95% CI 1.03; 5.04; p = 0.042) than etaner-
cept. The reasons for discontinuation included infections,
hypersensitivity, neuropsychiatric events, vasculitis, lymph-
oma (one patient) and others (Table 2).
Safety
A total of 1484 adverse events (AE) were reported, of
which there were 996 in patients receiving etanercept,
386 in patients receiving adalimumab and 102 in pa-
tients receiving tocilizumab. Of the adverse events, 148
were classified as serious adverse events (SAE), compris-
ing 119 patients on etanercept, 26 patients on adalimu-
mab and 3 patients on tocilizumab. Thus, the rates of
AE and SAE were significantly higher with etanercept
than with the other biologic agents (Table 3).
The AE and SAE were classified as adverse events of
special interest (AESI) if they represented new onset or
aggravation of uveitis (n = 88), serious or medically
important infections (n = 66), neutropenia (n = 26), hepa-
titis/elevated transaminases (n = 19), chronic inflamma-
tory bowel disease (CED, n = 14), intolerance (n = 7),
new onset of autoimmunity (n = 6), pregnancy (n = 6),
bleeding disorders (n = 5), hyperlipidemia (n = 4), stroke
(n = 2), malignancy (n = 1), thrombosis (n = 1), or demye-
lination (n = 1). There were no deaths.
Serious or medically important infections observed in
the etanercept cohort included pneumonia (n = 9), primary
Table 3 Safety
ADA ETA TOC ETA vs ADA ADA vs TOC ETA vs TOC
Patients, n 236; 236.4 419 74
Patient years, n 236.4 524,096 72,47364819
Exposure, years mean ± SD 1.00 ± 0.86 1.25 ± 1.05 0.98 ± 0.60
Adverse events, n; n/patient 386; 1.63 996; 2.37 102: 1.38 p = 0.011 p = 0.004
Rate/100 PY (95% CI) 163.3 (148.8; 180.4) 190.0 (178.6; 202.2) 140,7 (113.5; 167.4) RR 1.16 (1.03–1.31) ns RR 1.35 (1.1–1.66)
Serious adverse events,
n; n/patient
26; 0.11 119; 0.28 3; 0.04 p = 0.0008 p = 0.004
Rate/100 PY (95% CI) 11.0 (7.5; 16.2) 22.07 (19.0; 27.2) 4.1 (1.3; 12.8) RR 2.06 (1.35–3.16) ns RR 5.48 (1.74–17.25)
Autoimmunopathy,
n; n/patient
3; 0.012 2; 0.004 1; 0.014
Rate/100 PY (95% CI) 1.27 (0.41; 3.39) 0.38 (0.09; 1.53) 1.38 (0.19; 9.59) ns ns ns
Bleeding disorder,
n; n/patient
2; 0.008 3; 0.007 0
Rate/100 PY (95% CI) 0.85 (0.21; 3.38) 0.57 (0.18; 1.17) ns ns ns
CED, n; n/patient 1; 0.004 13; 0.031 0 p = 0.09
Rate/100 PY (95% CI) 0.42 (0.06; 3.0) 2.48 (1.44; 4.27) RR 5.86 (0.77–44.83) ns ns
Demyelinisation 0 1; 0.002 0
Rate/100 PY (95% CI) 0.19 (0.03-1.35) ns ns ns
Hepatitis 6; 0.025 10; 0.024 3; 0.041
Rate/100 PY (95% CI) 2.54 (1.14; 5.65) 1.91 (1.03; 3.55) 4.14 (1.31; 12.57) ns ns ns
Hyperlipidemia 0 3; 0.007 1; 0.014




13; 0.055 50; 0.119 3; 0.041 p = 0.076
Rate/100 PY (95% CI) 5.5 (3.19; 9.47) 9.54 (7.23; 12.59) 4.14 (1.31; 12.57) RR 1.73 (0.94–3.19) ns ns
Intolerance, n; n/patient 2; 0.008 3; 0.007 2; 0.027
Rate/100 PY (95% CI) 0.85 (0.21; 3.38) 0.57 (0.18; 1.17) 2.76 (0.68; 10.81) ns ns ns
Malignancy, n; n/patient 0 1; 0.002 0
Rate/100 PY (95% CI) 0.19 (0.03; 1.35) ns ns ns
ADA adalimumab, ETA etanercept, TOC tocilimuzab, PY person years, ns not significant, RR relative risk
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varicella (n = 7, none were vaccinated), zoster (n = 14), py-
elonephritis (n = 5), peritonitis (n = 2), appendicitis (n = 2)
and cellulitis (n = 2). The events observed with adalimu-
mab were pneumonia (n = 2), primary varicella (n = 4, none
were vaccinated), zoster (n = 3), osteomyelitis (n = 1), septic
arthritis [1] appendicitis (n = 1) and influenza (n = 1). For
tocilizumab, one case each of pneumonia, appendicitis and
influenza was reported. No cases of tuberculosis occurred,
and apart from herpes zoster, no opportunistic infections
were observed.
Some differences in the occurrence of specific AESI were
noted among the three treatment cohorts. Neutropenia
and serious or medically important infections occurred
with significantly greater frequency in the etanercept co-
hort compared with the adalimumab cohort. Aggravation
of uveitis occurred more frequently in the adalimumab co-
hort than in the tocilizumab cohort, whereas neutropenia
occurred significantly less frequently. Compared with the
tocilizumab cohort, aggravation and new onset of uveitis
occurred more frequently in the etanercept cohort.
Notably, serious or medically important infections and
events of chronic inflammatory bowel disease occurred
more frequently in the etanercept cohort than in the
adalimumab cohort. However, this difference was not
significant (p < 0.05, Table 3).
Discussion
To our knowledge, this is the first study to directly com-
pare adalimumab, etanercept, and tocilizumab as therapy
for polyarticular JIA. Data analysis was restricted to pa-
tients initiating treatment after 2011, when tocilizumab
became available for the treatment of JIA. The patient
population was further restricted to patients with
rheumatoid factor-positive or rheumatoid factor-negative
polyarthritis and extended oligoarthritis. Patients with sys-
temic JIA (sJIA), enthesitis-related arthritis (ERA) and
psoriatic arthritis (PsA) were excluded to acquire a more
homogenous patient population and to avoid the effect of
differences in approval among the respective drugs;
etanercept is approved for ERA and PsA, adalimumab for
ERA and tocilizumab for sJIA.
Etanercept was approved for polyarticular JIA in 2000,
and adalimumab was approved in 2008. Therefore, con-
siderably more experience has been gained with etaner-
cept than with adalimumab or tocilizumab. Accordingly,
etanercept was used much more frequently than either
adalimumab or tocilizumab. In the Dutch ABC registry,
etanercept was also the most frequently prescribed
biologic agent for non-systemic JIA [20]. In that study,
greater drug experience was the most important factor
driving the decision to use etanercept rather than adali-
mumab. Adalimumab was favored by Dutch pediatric
rheumatologists for patients who had preceding uveitis.
Similar findings were obtained in the current BIKER
population.
For German pediatric rheumatologists, we may specu-
late that the number of patients starting on etanercept
as their first biologic agent is higher because there is
prolonged experience with etanercept compared to the
other biologic agents. Adalimumab was predominantly
chosen as the first biologic agent in patients with
concomitant uveitis. Finally, the relative rarity of using
tocilizumab can either be attributed to the fact that first,
it is the biologic agent with the least experience of use
and second, that currently only the intravenous infusion
is approved, which means it can only be used in centers
with an infusion facility. The decision as to which bio-
logic agent is used is not influenced by a protocol, algo-
rithm, national recommendation or guideline, or by the
registry itself. Adalimumab was used more frequently
than etanercept as a second-line biologic agent but had
comparable efficacy in both second-line and first-line
users [12].
There were few other differences among the studied
cohorts. Patients in the adalimumab or tocilizumab co-
horts were older than those in the etanercept cohort,
and there were fewer patients with extended oligoarthri-
tis in the tocilizumab cohort. A striking difference was
observed in use of concomitant MTX, which was much
more common in the etanercept cohort, followed by the
adalimumab cohort. Fewer than 50% of the patients in
the tocilizumab cohort received concomitant MTX ther-
apy. This observation was surprising because etanercept
is approved only for monotherapy, whereas both of the
other biologic agents are also approved for combination
therapy.
Despite these differences, PedACR treatment response
rates were comparable for all three biologic agents. The
majority of patients demonstrated marked improvement
after 3 months of treatment. The response rates thereafter
remained stable or increased further. No apparent differ-
ences among the three treatment cohorts were noted, in
accordance with the response rates observed in open-label
phases of the pivotal randomized controlled withdrawal
studies of each of the drugs [6, 13, 21]. However, in the
most recent clinical trial investigating etanercept, patients
with extended oligoarticular JIA experienced a much
higher rate of clinical improvement [9].
There was a small but significant difference in reported
absolute disease activity at baseline, as measured by the
JADAS10, which was highest in the tocilizumab cohort
and lowest in the adalimumab cohort. This difference was
balanced by the inverse probability of treatment allocation
estimated by a generalized propensity score. The JADAS
score fell significantly in all cohorts after treatment. The
residual JADAS at the last observation (mean observation
time in all cohorts of approximately 1 year) was highest in
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the etanercept cohort. The greatest adjusted mean reduc-
tion in the JADAS was observed in the etanercept cohort;
in contrast, the greatest observed mean reduction was in
the tocilizumab cohort.
As tocilizumab may have had a higher influence on
the acute phase response via its inhibitory capability on
the IL-6 axis, the JADAS10 and the clinical JADAS
(cJADAS), which considers only three clinical parame-
ters were compared. Interestingly, at baseline 144 of 407
patients (35.4%) in the etanercept cohort and 26 of 74
patients (35.1%) in the tocilizumab cohort had higher
classic JADAS than cJADAS. Upon treatment (month 3
to 24), 91 of 856 patients (10.6%) in the etanercept co-
hort and 22 of 187 patients (12.4%) from the tocilizumab
cohort had higher classic JADAS than cJADAS. Thus,
both at baseline and after treatment the results were
very much comparable, and direct inhibition of IL-6
seems not to influence the laboratory parameters of the
JADAS10 more than TNF inhibition. As we used defini-
tions for MDA and remission based on the complete
JADAS, the original JADAS10 was preferred over the
cJADAS, which considers only three clinical parameters.
Comparable numbers of patients achieved JADAS remis-
sion and JADAS minimal disease activity in a large data-
base study [16, 18]. No differences were identified
among the cohorts in terms of either speed to remis-
sion/MDA or absolute remission/MDA rates.
Interestingly, the drug survival rates for the three bio-
logic agents were different in this study. Whereas etaner-
cept and tocilizumab showed comparable drug survival,
significantly more patients discontinued adalimumab.
The main reason for adalimumab discontinuation was
lack of therapeutic response or inefficacy, which differed
significantly compared with the discontinuation fre-
quency with etanercept due to inefficacy/lack of thera-
peutic effect. This could have been influenced by the
higher proportion of patients on MTX in the etanercept
cohort. It is possible that Adalimumab in monotherapy
could lead to more immunogenicity and secondary loss
of efficacy.
Remission was the second leading reason for drug dis-
continuation. Significantly fewer patients discontinued
tocilizumab than etanercept for reasons of remission.
This finding is remarkable because the rates of JADAS
remission were not different. The mean/median duration
of treatment with both etanercept and tocilizumab were
comparable. There were also no differences in the num-
ber of patients on prolonged treatment: a quarter of the
patients had been treated with etanercept for more than
1.7 years, which was comparable to more than 1.5 years
in a quarter of the patients using tocilizumab. It is likely
that tocilizumab adherence was affected by its more fre-
quent use as a second-line biologic agent compared with
etanercept and thus an earlier biologic treatment had
failed. It can be speculated that in this situation, success-
ful drug treatment likely will not be discontinued.
Very few patients discontinued their biologic agent due
to intolerance, which suggests that they are not only very
effective but also very well-tolerated. The pattern of AE
observed in this study of patients with pJIA is consistent
with the known safety profile of adalimumab, etanercept
and tocilizumab [6, 10, 13]. Interestingly, there were no
cases of tuberculosis. Apart from herpes zoster, which has
been regarded as an opportunistic infection by some
authors, no other opportunistic infections were reported.
Furthermore, only one case of malignancy was reported,
in which an Epstein-Barr virus (EBV)-associated lymph-
oma developed in a child who had been treated with
MTX and etanercept. This observation is preliminary due
to the short observation period of this analysis to compare
biologic agents used contemporaneously, thus restricting
the analysis to patients treated after 2011. Notably, a
significant number of malignancies have been observed in
the BIKER registry since 2001 [22, 23].
The observed discontinuation rate was comparable to
that reported in an Italian cohort, in which 165 of 301
patients with various categories of JIA discontinued
biologic treatment [24]. The majority (135 patients) dis-
continued for reasons of treatment failure, including a
lack or loss of efficacy, and AE. Most patients discontin-
ued due to intolerance (34.6%), which was very different
compared with our cohort. This discrepancy can be
explained, in part, by the frequent use of infliximab in
the Italian cohort. Among this cohort, 39% of patients
discontinued biologic treatment due to adverse events.
Because infliximab is not approved for JIA in Germany,
it cannot by studied systematically in BIKER.
In the present analysis, the overall safety of the biologic
agents was acceptable. The rate of serious or medically
important infections (4.1–9.5/100 patient-years) was com-
parable to that observed in other registry cohorts. In a
British cohort, medically important infections occurred
more frequently among users of TNF inhibitors than in a
non-biologic control cohort, but the rate of serious infec-
tions was not significantly different [25]. Interestingly, new
onset Crohn’s disease or ulcerative colitis mostly occurred
in the etanercept cohort, which is consistent with previous
findings [26]. Etanercept has been shown to lack efficacy
toward CED [27]. However, the rate of uveitis was highest
in the adalimumab cohort, which could be attributed to a
selection bias, as described previously [28]. Patients with
uveitis as a comorbidity had a four times higher chance of
receiving adalimumab rather than etanercept [28]. Other
AESI were reported infrequently. It is interesting to note
that the rates of reported neutropenia, hyperlipidemia or
elevated liver enzymes were not higher in the tocilizumab
cohort, as might be expected based on analyses conducted
in adult patients with rheumatoid arthritis [27].
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The results from randomized controlled trials (RCT)
cannot easily be extrapolated to routine care. Several
specific features of the RCT must be considered. The
inclusion and exclusion criteria may be responsible for a
more homogenous study population; for example, co-
morbidities and concomitant drugs are usually exclusion
criteria. Clinical control is tighter, prescribing practices
are more stringent in a trial over time, and drug adher-
ence may be influenced by the desire to retain a patient
in the study. Thus, the RCT population may not reflect
routine clinical care. By comparison, registry analyses re-
flect routine care and may, in part, be superior to RCTs
despite having other limitations.
Observational studies of cohorts of unselected patients
receiving routine care may allow better comparisons of
the drugs used, although the lack of randomization must
be considered when interpreting the results. In a smaller
Dutch observational study of 214 patients with JIA [29],
the use of etanercept and adalimumab was evaluated in
routine care; however, neither the efficacy nor the sur-
vival rates were compared.
Our results reflect clinical practice and do not include
the very early introduction of biologic agents, which has
been evaluated in the TREAT and ACUTE-JIA studies
[30, 31]. Furthermore, the observations obtained from a
registry are not a substitute for clinical trials. Compara-
tive head-to-head studies with biologic agents in juvenile
idiopathic arthritis as performed in adult patients with
rheumatoid arthritis would be an ideal approach, but the
lower prevalence of JIA may render this an unrealistic
target.
Conclusions
So far, in clinical practice etanercept remains the most
frequently used first-line biologic agent for the treat-
ment of polyarticular JIA. The three biologic agents
adalimumab, etanercept and tocilizumab had compar-
able efficacy. Overall, tolerance was acceptable. Inter-
estingly, compliance was highest with tocilizumab and
lowest with adalimumab. This study provides the first
indication for the comparison of different biologic
agents in polyarticular JIA based on observational study
data, with all their weaknesses, and demonstrates the
need for well-controlled head-to-head studies for
confirmation.
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